Prosight Management, LP Adc Therapeutics Sa Transaction History
Prosight Management, LP
- $337 Million
- Q4 2024
A detailed history of Prosight Management, LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Prosight Management, LP holds 9,515,000 shares of ADCT stock, worth $15.9 Million. This represents 5.62% of its overall portfolio holdings.
Number of Shares
9,515,000
Previous 9,636,237
1.26%
Holding current value
$15.9 Million
Previous $30.4 Million
37.62%
% of portfolio
5.62%
Previous 8.15%
Shares
10 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
55.3MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$26.2 Million2.44% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$9.97 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$6.61 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$5.94 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA1.93MShares$3.23 Million0.03% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $130M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...